[go: up one dir, main page]

MX2010002116A - Un modulador de nrg1 para el tratamiento de trastornos respiratorios. - Google Patents

Un modulador de nrg1 para el tratamiento de trastornos respiratorios.

Info

Publication number
MX2010002116A
MX2010002116A MX2010002116A MX2010002116A MX2010002116A MX 2010002116 A MX2010002116 A MX 2010002116A MX 2010002116 A MX2010002116 A MX 2010002116A MX 2010002116 A MX2010002116 A MX 2010002116A MX 2010002116 A MX2010002116 A MX 2010002116A
Authority
MX
Mexico
Prior art keywords
nrg1
treatment
modulators
relates
modulator
Prior art date
Application number
MX2010002116A
Other languages
English (en)
Inventor
Carol Elizabeth Jones
Alan Jackson
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2010002116A publication Critical patent/MX2010002116A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a moduladores de la familia de Neurregulina (NRO), en particular NRG1, y más particularmente la NRGß, y de una manera muy particular la NRG1ß1. La presente invención también se refiere al uso de estos moduladores para inhibir la hiperplasia de células caliciformes, y por consiguiente, también se refiere al uso de estos moduladores en el tratamiento o en la prevención de enfermedades y trastornos humanos que presenten una producción patológica de moco, tal como enfermedad pulmonar obstructiva crónica (COPD), fibrosis quística (CF), bronquitis crónica, y asma.
MX2010002116A 2007-08-24 2008-08-22 Un modulador de nrg1 para el tratamiento de trastornos respiratorios. MX2010002116A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07114972 2007-08-24
PCT/EP2008/061009 WO2009027332A1 (en) 2007-08-24 2008-08-22 A modulator of nrg1 for treatment of respiratory disorders

Publications (1)

Publication Number Publication Date
MX2010002116A true MX2010002116A (es) 2010-03-26

Family

ID=38668734

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010002116A MX2010002116A (es) 2007-08-24 2008-08-22 Un modulador de nrg1 para el tratamiento de trastornos respiratorios.

Country Status (11)

Country Link
US (2) US20110070247A1 (es)
EP (1) EP2192955A1 (es)
JP (1) JP2010536830A (es)
KR (1) KR20100046215A (es)
CN (1) CN101784302A (es)
AU (1) AU2008292262B2 (es)
BR (1) BRPI0816142A2 (es)
CA (1) CA2697378A1 (es)
EA (1) EA201000337A1 (es)
MX (1) MX2010002116A (es)
WO (1) WO2009027332A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103959065B (zh) 2011-10-06 2018-07-17 Aveo制药公司 预测肿瘤对抗erbb3抗体的应答
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
EP4276108A3 (en) 2016-04-27 2024-01-24 AbbVie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
WO2021142245A1 (en) * 2020-01-10 2021-07-15 Translate Bio, Inc. Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6846799B1 (en) * 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US20050208527A1 (en) * 2000-02-28 2005-09-22 Decode Genetics Ehf. Human schizophrenia gene
US20020045577A1 (en) * 2000-02-28 2002-04-18 Decode Genetics Human schizophrenia gene
JPWO2006062135A1 (ja) * 2004-12-07 2008-06-12 独立行政法人理化学研究所 精神疾患の診断薬
JP2008535795A (ja) * 2005-03-07 2008-09-04 ターゲッティド・モレキュラー・ダイアグナスティクス・エルエルシー チロシンキナーゼインヒビター組成物、並びに疾患の治療におけるそれらの製造及び使用のための方法
US20070036797A1 (en) * 2005-06-02 2007-02-15 Galaxy Biotech, Llc Methods of treating brain tumors with antibodies
US20070213264A1 (en) * 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof

Also Published As

Publication number Publication date
US8658165B2 (en) 2014-02-25
EP2192955A1 (en) 2010-06-09
BRPI0816142A2 (pt) 2015-02-18
AU2008292262A1 (en) 2009-03-05
JP2010536830A (ja) 2010-12-02
US20110070247A1 (en) 2011-03-24
US20130034567A1 (en) 2013-02-07
KR20100046215A (ko) 2010-05-06
CN101784302A (zh) 2010-07-21
CA2697378A1 (en) 2009-03-05
EA201000337A1 (ru) 2010-10-29
AU2008292262B2 (en) 2012-05-31
WO2009027332A1 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
MX2011010908A (es) Anticuerpos anti-tnf-alfa y sus usos.
MX2009005935A (es) Compuestos biciclicos y su uso como anti-diabeticos.
MY156777A (en) Substituted 2-acetamido-5-ary1-1,2,4-triazolones and use thereof
JO2756B1 (en) The second preparation of aqueous pyrimidnon containing 4- (4-ciano-2-2 thiourail) and its use)
WO2011090738A3 (en) Type ii raf kinase inhibitors
MX2009013990A (es) Metodos para tratar enfermedades y trastornos mediados por serotonina.
UA90048C2 (ru) Кондиционированная композиция и способ ее получения
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
WO2006125640A3 (en) Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
MY161415A (en) A homeopathic formulation
IL212958B (en) Placental stem cells for the treatment of diseases, syndromes or conditions of the lungs
UA102065C2 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
WO2009089635A9 (en) Treating neurodegenerative diseases with progranulin (pgrn)
PH12014500075A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2009004108A (es) Compuestos de tetrahidropirrolopiracina sustituidos teniendo afinidad al canal kcnq2/3 k+ y su uso en farmacos.
EP4406536A3 (en) Cystathionine beta-synthase enzyme for treatment of homocystinuria
MY149606A (en) Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
MX2011012666A (es) Usos de anticuerpos il-1beta y sus fragmentos de union relacionados con eventos cardiovasculares.
WO2012065110A3 (en) S-protected cysteine analogs and related compounds
MX2010002116A (es) Un modulador de nrg1 para el tratamiento de trastornos respiratorios.
WO2011075606A3 (en) Hyperglycosylated polypeptide variants and methods of use
MY150931A (en) Substituted oxazolidinones and their use
MX2013002121A (es) Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.

Legal Events

Date Code Title Description
FG Grant or registration